Edition:
United Kingdom

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

1.30USD
8:39pm GMT
Change (% chg)

$-0.09 (-6.47%)
Prev Close
$1.39
Open
$1.39
Day's High
$1.40
Day's Low
$1.28
Volume
186,641
Avg. Vol
165,563
52-wk High
$6.59
52-wk Low
$1.01

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $396.17
Shares Outstanding(Mil.): 51.05
Dividend: --
Yield (%): --

Financials

  TTPH.OQ Industry Sector
P/E (TTM): -- 30.48 33.71
EPS (TTM): -2.81 -- --
ROI: -73.69 14.98 14.48
ROE: -73.76 16.31 15.99

FDA approves Tetraphase Pharma's antibiotic

Tetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.

27 Aug 2018

UPDATE 1-U.S. FDA approves Tetraphase Pharma's antibiotic

Aug 27 Tetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.

27 Aug 2018

U.S. FDA approves Tetraphase Pharma's antibiotic

Aug 27 The U.S. Food and Drug Administration on Monday approved Tetraphase Pharmaceuticals Inc's antibiotic for complicated intra-abdominal infections, providing a new option to combat the growing problem of treatment-resistant bacteria.

27 Aug 2018

Earnings vs. Estimates